Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant848 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,877 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07734116 | A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma. | recruiting | Phase 1 / Phase 2 | 50 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05515575 | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA | active not recruiting | Phase 2 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06541262 | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 104 | Milton S. Hershey Medical CenterOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07725380 | Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma | recruiting | Phase 1 / Phase 2 | 74 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801222 | A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma | not yet recruiting | Phase 1 / Phase 2 | 70 | SOTIO Biotech a.s.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | recruiting | Phase 2 | 124 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04374305 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)(INTUITT-NF2) | recruiting | Phase 2 | 109 | Scott R. Plotkin, MD, PhDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05918640 | Lurbinectedin in FET-Fused Tumors(LiFFT) | recruiting | Phase 1 / Phase 2 | 63 | Children's Hospital of PhiladelphiaOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07328425 | Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS(ISG-TULIPS) | recruiting | Phase 2 | 20 | Italian Sarcoma GroupNETWORK | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06898970 | Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma | recruiting | Phase 2 | 18 | Varun Monga, MBBSOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07428993 | Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma | recruiting | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01799538 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | recruiting | Phase 1 / Phase 2 | 100 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04298541 | Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05493215 | Imatinib TDM in GIST | recruiting | Phase 2 | 28 | Reema A. PatelOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07460986 | A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.(BEXAR) | recruiting | Phase 1 / Phase 2 | 278 | MedSIROTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03331250 | Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) | completed | Phase 2 | 13 | Massachusetts General HospitalOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | active not recruiting | Phase 1 / Phase 2 | 62 | Massachusetts General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06389799 | A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)(PERELI) | recruiting | Phase 2 | 33 | Lund University HospitalOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07516925 | A Study of Ivonescimab in People With Leiomyosarcoma | recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03356782 | Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04044768 | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | active not recruiting | Phase 2 | 52 | USWM CT, LLCINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT04433221 | Combination Immunotherapy Targeting Sarcomas | not yet recruiting | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787429 | Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma(Dragonfly) | recruiting | Phase 2 | 40 | Anna RaciborskaOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04941274 | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06975293 | STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas | recruiting | Phase 1 / Phase 2 | 107 | STORM Therapeutics LTDINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07308886 | Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) | recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04303117 | PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | recruiting | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05253131 | Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas | recruiting | Phase 2 | 41 | University of Alabama at BirminghamOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781891 | RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT | not yet recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01946529 | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | completed | Phase 2 | 24 | St. Jude Children's Research HospitalOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03965234 | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases | recruiting | Phase 1 / Phase 2 | 99 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05968768 | To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) | recruiting | Phase 2 | 24 | Anna RaciborskaOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06820957 | Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body | active not recruiting | Phase 2 / Phase 3 | 2 | Children's Oncology GroupNETWORK | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07283731 | Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT02243605 | Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma | active not recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00407433 | Clinical Studies of Gemcitabine-Oxaliplatin | completed | Phase 2 | 156 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01267955 | Vismodegib in Treating Patients With Advanced Chondrosarcomas | active not recruiting | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07150806 | RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | recruiting | Phase 1 / Phase 2 | 30 | Joshua PalmerOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05642455 | SPEARHEAD-3 Pediatric Study | recruiting | Phase 1 / Phase 2 | 20 | USWM CT, LLCINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05797662 | A Study of Propranolol to Treat Kaposi Sarcoma | not yet recruiting | Phase 2 | 25 | AIDS Malignancy ConsortiumNETWORK | 5 | Aug 11, 2026 | clinicaltrials |
| NCT07549022 | Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor | recruiting | Phase 1 / Phase 2 | 17 | Ankit Mangla, MDOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03851614 | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors(DAPPER) | active not recruiting | Phase 2 | 90 | University Health Network, TorontoOTHER | 1 | Aug 10, 2026 | clinicaltrials |
Data updated 21 days agoSource updated Sep 8, 2026source: clinicaltrials